{"analyses":[{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.77","estimateComment":"Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds","groupDescription":"Anti HPV 16","groupIds":["OG000","OG001"],"nonInferiorityComment":"Non-inferiority of GMT in 27-45 year-olds relative to 16-26 year-olds was demonstrated if the lower limit of the 95% confidence interval (CI) for the fold difference was greater than 0.5.","nonInferiorityType":"NON_INFERIORITY","pValue":"< 0.001","pValueComment":"Analysis of variance (ANOVA) model with response of log individual titers and a fixed effect for age groups.","paramType":"Fold Difference","paramValue":"0.70","statisticalMethod":"ANOVA"},{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.80","estimateComment":"Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds","groupDescription":"Anti HPV 18","groupIds":["OG000","OG001"],"nonInferiorityComment":"Non-inferiority of GMT in 27-45 year-olds relative to 16-26 year-olds was demonstrated if the lower limit of the 95% confidence interval (CI) for the fold difference was greater than 0.5.","nonInferiorityType":"NON_INFERIORITY","pValue":"< 0.001","pValueComment":"Analysis of variance (ANOVA) model with response of log individual titers and a fixed effect for age groups.","paramType":"Fold Difference","paramValue":"0.71","statisticalMethod":"ANOVA"},{"ciLowerLimit":"0.60","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.74","estimateComment":"Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds","groupDescription":"Anti HPV 31","groupIds":["OG000","OG001"],"nonInferiorityComment":"Non-inferiority of GMT in 27-45 year-olds relative to 16-26 year-olds was demonstrated if the lower limit of the 95% confidence interval (CI) for the fold difference was greater than 0.5.","nonInferiorityType":"NON_INFERIORITY","pValue":"< 0.001","pValueComment":"ANOVA model with response of log individual titers and a fixed effect for age groups.","paramType":"Fold Difference","paramValue":"0.66","statisticalMethod":"ANOVA"},{"ciLowerLimit":"0.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.80","estimateComment":"Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds","groupDescription":"Anti HPV 33","groupIds":["OG000","OG001"],"nonInferiorityComment":"Non-inferiority of GMT in 27-45 year-olds relative to 16-26 year-olds was demonstrated if the lower limit of the 95% confidence interval (CI) for the fold difference was greater than 0.5.","nonInferiorityType":"NON_INFERIORITY","pValue":"< 0.001","pValueComment":"ANOVA model with response of log individual titers and a fixed effect for age groups.","paramType":"Fold Difference","paramValue":"0.73","statisticalMethod":"ANOVA"},{"ciLowerLimit":"0.60","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.76","estimateComment":"Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds","groupDescription":"Anti HPV 45","groupIds":["OG000","OG001"],"nonInferiorityComment":"Non-inferiority of GMT in 27-45 year-olds relative to 16-26 year-olds was demonstrated if the lower limit of the 95% confidence interval (CI) for the fold difference was greater than 0.5.","nonInferiorityType":"NON_INFERIORITY","pValue":"< 0.001","pValueComment":"ANOVA model with response of log individual titers and a fixed effect for age groups.","paramType":"Fold Difference","paramValue":"0.68","statisticalMethod":"ANOVA"},{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.78","estimateComment":"Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds","groupDescription":"Anti HPV 52","groupIds":["OG000","OG001"],"nonInferiorityComment":"Non-inferiority of GMT in 27-45 year-olds relative to 16-26 year-olds was demonstrated if the lower limit of the 95% confidence interval (CI) for the fold difference was greater than 0.5.","nonInferiorityType":"NON_INFERIORITY","pValue":"< 0.001","pValueComment":"ANOVA model with response of log individual titers and a fixed effect for age groups.","paramType":"Fold Difference","paramValue":"0.71","statisticalMethod":"ANOVA"},{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.76","estimateComment":"Fold difference calculated as GMT 27-45 year-olds/GMT 16-26 year-olds","groupDescription":"Anti HPV 58","groupIds":["OG000","OG001"],"nonInferiorityComment":"Non-inferiority of GMT in 27-45 year-olds relative to 16-26 year-olds was demonstrated if the lower limit of the 95% confidence interval (CI) for the fold difference was greater than 0.5.","nonInferiorityType":"NON_INFERIORITY","pValue":"< 0.001","pValueComment":"ANOVA model with response of log individual titers and a fixed effect for age groups.","paramType":"Fold Difference","paramValue":"0.69","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"732.5","upperLimit":"847.2","value":"787.8"},{"groupId":"OG001","lowerLimit":"594.9","upperLimit":"685.0","value":"638.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"448"}],"units":"Participants"}],"title":"Anti-HPV 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"558.7","upperLimit":"641.6","value":"598.7"},{"groupId":"OG001","lowerLimit":"424.1","upperLimit":"485.0","value":"453.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"448"}],"units":"Participants"}],"title":"Anti-HPV 11"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2863.4","upperLimit":"3303.9","value":"3075.8"},{"groupId":"OG001","lowerLimit":"2001.1","upperLimit":"2304.5","value":"2147.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"436"},{"groupId":"OG001","value":"448"}],"units":"Participants"}],"title":"Anti-HPV 16"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"685.0","upperLimit":"809.1","value":"744.5"},{"groupId":"OG001","lowerLimit":"491.8","upperLimit":"575.7","value":"532.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"471"}],"units":"Participants"}],"title":"Anti-HPV 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"551.1","upperLimit":"644.9","value":"596.1"},{"groupId":"OG001","lowerLimit":"367.0","upperLimit":"426.6","value":"395.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"447"},{"groupId":"OG001","value":"488"}],"units":"Participants"}],"title":"Anti-HPV 31"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"331.7","upperLimit":"378.9","value":"354.5"},{"groupId":"OG001","lowerLimit":"242.9","upperLimit":"276.1","value":"259.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"493"}],"units":"Participants"}],"title":"Anti-HPV 33"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"197.7","upperLimit":"233.7","value":"214.9"},{"groupId":"OG001","lowerLimit":"134.4","upperLimit":"157.7","value":"145.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"470"},{"groupId":"OG001","value":"515"}],"units":"Participants"}],"title":"Anti-HPV 45"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"324.0","upperLimit":"370.5","value":"346.5"},{"groupId":"OG001","lowerLimit":"229.4","upperLimit":"261.0","value":"244.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"456"},{"groupId":"OG001","value":"496"}],"units":"Participants"}],"title":"Anti-HPV 52"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"399.4","upperLimit":"458.6","value":"428.0"},{"groupId":"OG001","lowerLimit":"277.1","upperLimit":"317.0","value":"296.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"451"},{"groupId":"OG001","value":"478"}],"units":"Participants"}],"title":"Anti-HPV 58"}],"denoms":[{"counts":[{"groupId":"OG000","value":"485"},{"groupId":"OG001","value":"533"}],"units":"Participants"}],"description":"Antibodies to the HPV types contained in V503 were measured using a competitive luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL). Statistical comparisons between arms was performed for the HPV types considered oncogenic (HPV Types 16/18/31/33/45/52/58).","dispersionType":"95% Confidence Interval","groups":[{"description":"Young adult women 16- to 26-years old received V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.","id":"OG000","title":"Women 16-26 Years of Age"},{"description":"Adult women 27- to 45-years old received V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.","id":"OG001","title":"Women 27-45 Years of Age"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Received all 3 vaccinations of the correct dose and within acceptable day ranges, had evaluable serology results at Day 1 and Month 7, must have been seronegative to the appropriate HPV type at Day 1 and had no protocol deviations that could interfere with the evaluation of participant's immune response to the 9vHPV vaccine.","reportingStatus":"POSTED","timeFrame":"4 weeks post vaccination 3 (Month 7)","title":"Anti-HPV Geometric Mean Titers (GMTs) for Each Anti-HPV Type","type":"PRIMARY","unitOfMeasure":"mMU/mL"}